Arena shares slip after Merck dumps pact

Shares of Arena Pharmaceuticals slipped six percent after the developer announced that Merck is dropping out of their collaboration on a new atherosclerosis therapy. Merck decided to opt out after MK-1903 flunked a mid-stage trial.  Story

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.